Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia

Frontiers in Genetics

Volumn 5, Issue DEC, 2014, Pages

  Tillet, Emmanuelle ^a,b,c   Bailly, Sabine ^a,b,c  

^a INSERM   (France)

^b CEA GRENOBLE   (France)

^c UNIV GRENOBLE ALPES   (France)

Author keywords

ALK1; BMP10; BMP9; Cell signaling; Endoglin; Hereditary hemorrhagic telangiectasia

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 10; BONE MORPHOGENETIC PROTEIN 9; ENDOGLIN; PROTEIN SERINE THREONINE KINASE; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; BEVACIZUMAB; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CYTOKINE; SMAD 5 PROTEIN; SMAD 8 PROTEIN; SMAD1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA3;

ANGIOGENESIS; ARTERIOVENOUS MALFORMATION; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONGENITAL BLOOD VESSEL MALFORMATION; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; HEART MUSCLE CELL; HUMAN; LYMPH VESSEL; LYMPHATIC DRAINAGE; MUTATION; NONHUMAN; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN EXPRESSION; RENDU OSLER WEBER DISEASE; SIGNAL TRANSDUCTION; VASCULARIZATION; VASODILATATION; ZEBRA FISH; BINDING AFFINITY; ENZYME ACTIVITY; GENE MUTATION; HAPLOINSUFFICIENCY; PROTEIN SYNTHESIS REGULATION; REVIEW; STIMULUS RESPONSE; VASCULAR REMODELING;

EID: 84917672957     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2014.00456     Document Type: Article

References (74)

1. Alt, A., Miguel-Romero, L., Donderis, J., Aristorena, M., Blanco, F.J., Round, A., Rubio, V., Bernabeu, C., and Marina, A. (2012). Structural and functional insights into endoglin ligand recognition and binding. PLoS One 7, e29948. doi: 10.1371/journal.pone.0029948.
2. Arthur, H.M., Ure, J., Smith, A.J., Renforth, G., Wilson, D.I., Torsney, E., Charlton, R., Parums, D.V., Jowett, T., Marchuk, D.A., Burn, J., and Diamond, A.G. (2000). Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 217, 42-53.
3. Atri, D., Larrivee, B., Eichmann, A., and Simons, M. (2013). Endothelial signaling and the molecular basis of arteriovenous malformation. Cell Mol Life Sci. doi: 10.1007/s00018-013-1475-1.
4. Barbara, N.P., Wrana, J.L., and Letarte, M. (1999). Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 274, 584-594.
5. Bellon, T., Corbi, A., Lastres, P., Cales, C., Cebrian, M., Vera, S., Cheifetz, S., Massague, J., Letarte, M., and Bernabeu, C. (1993). Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. European Journal of Immunology 23, 2340-2345.
6. Bidart, M., Ricard, N., Levet, S., Samson, M., Mallet, C., David, L., Subileau, M., Tillet, E., Feige, J.J., and Bailly, S. (2012). BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain. Cell Mol Life Sci 69, 313-324.
7. Bourdeau, A., Dumont, D.J., and Letarte, M. (1999). A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104,1343-1351. doi: 10.1172/JCI8088.
8. Bourdeau, A., Faughnan, M.E., and Letarte, M. (2000). Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 10, 279-285.
9. Briggs, L.E., Phelps, A.L., Brown, E., Kakarla, J., Anderson, R.H., Van Den Hoff, M.J., and Wessels, A. (2013). Expression of the BMP receptor Alk3 in the second heart field is essential for development of the dorsal mesenchymal protrusion and atrioventricular septation. CircRes 112,1420-1432.
10. Brown, M.A., Zhao, Q., Baker, K.A., Naik, C., Chen, C., Pukac, L., Singh, M., Tsareva, T., Parice, Y., Mahoney, A., Roschke, V., Sanyal, I., and Choe, S. (2005). Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem 280, 25111-25118.
11. Castonguay, R., Werner, E.D., Matthews, R.G., Presman, E., Mulivor, A.W., Solban, N., Sako, D., Pearsall, R.S., Underwood, K.W., Seehra, J., Kumar, R., and Grinberg, A.V. (2011). Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem 286, 30034-30046.
12. Chen, H., Brady Ridgway, J., Sai, T., Lai, J., Warming, S., Chen, H., Roose-Girma, M., Zhang, G., Shou, W., and Yan, M. (2013). Context-dependent signaling defines roles of BMP9 and BMP10 in embryonic and postnatal development. Proc Natl Acad Sci USA 110, 11887-11892.
13. Chen, H., Shi, S., Acosta, L., Li, W., Lu, J., Bao, S., Chen, Z., Yang, Z., Schneider, M.D., Chien, K.R., Conway, S.J., Yoder, M.C., Haneline, L.S., Franco, D., and Shou, W. (2004). BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. Development 131,2219-2231.
14. Corti, P., Young, S., Chen, C.Y., Patrick, M.J., Rochon, E.R., Pekkan, K., and Roman, B.L. (2011). Interaction between alk1 and blood flow in the development of arteriovenous malformations. Development 138,1573-1582.
15. Cymerman, U., Vera, S., Pece-Barbara, N., Bourdeau, A., White, R.I., Jr., Dunn, J., and Letarte, M. (2000). Identification of hereditary hemorrhagic telangiectasia type 1 in newborns by protein expression and mutation analysis of endoglin. Pediatr Res 47, 24-35.
16. David, L., Feige, J.J., and Bailly, S. (2009). Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev 20, 203-212.
17. David, L., Mallet, C., Keramidas, M., Lamande, N., Gasc, J.M., Dupuis-Girod, S., Plauchu, H., Feige, J.J., and Bailly, S. (2008). Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res 102, 914-922.
18. David, L., Mallet, C., Mazerbourg, S., Feige, J.J., and Bailly, S. (2007). Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109,1953-1961.
19. Dupuis-Girod, S., Ginon, I., Saurin, J.C., Marion, D., Guillot, E., Decullier, E., Roux, A., Carette, M.F., Gilbert-Dussardier, B., Hatron, P.Y., Lacombe, P., Lorcerie, B., Riviere, S., Corre, R., Giraud, S., Bailly, S., Paintaud, G., Ternant, D., Valette, P.J., Plauchu, H., and Faure, F. (2012). Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307, 948-955.
20. Dyer, L.A., Pi, X., and Patterson, C. (2014). The role of BMPs in endothelial cell function and dysfunction. Trends Endocrinol Metab 25, 472-480.
21. Flieger, D., Hainke, S., and Fischbach, W. (2006). Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 85, 631-632.
22. Forg, T., Hafner, M., and Lux, A. (2014). Investigation of endoglin wild-type and missense mutant protein heterodimerisation using fluorescence microscopy based IF, BiFC and FRET Analyses. PLoS One 9, e102998. doi: 10.1371/journal.pone.0102998.
23. Gallione, C., Aylsworth, A.S., Beis, J., Berk, T., Bernhardt, B., Clark, R.D., Clericuzio, C., Danesino, C., Drautz, J., Fahl, J., Fan, Z., Faughnan, M.E., Ganguly, A., Garvie, J., Henderson, K., Kini, U., Leedom, T., Ludman, M., Lux, A., Maisenbacher, M., Mazzucco, S., Olivieri, C., Ploos Van Amstel, J.K., Prigoda-Lee, N., Pyeritz, R.E., Reardon, W., Vandezande, K., Waldman, J.D., White, R.I., Jr., Williams, C.A., and Marchuk, D.A. (2010). Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JPHHT syndrome. Am J Med Genet A 152A, 333-339.
24. Gallione, C.J., Repetto, G.M., Legius, E., Rustgi, A.K., Schelley, S.L., Tejpar, S., Mitchell, G., Drouin, E., Westermann, C.J., and Marchuk, D.A. (2004). A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 363, 852-859.
25. Gallione, C.J., Richards, J.A., Letteboer, T.G., Rushlow, D., Prigoda, N.L., Leedom, T.P., Ganguly, A., Castells, A., Ploos Van Amstel, J.K., Westermann, C.J., Pyeritz, R.E., and Marchuk, D.A. (2006). SMAD4 mutations found in unselected HHT patients. J Med Genet 43, 793-797.
26. Girerd, B., Montani, D., Coulet, F., Sztrymf, B., Yaici, A., Jais, X., Tregouet, D., Reis, A., Drouin-Garraud, V., Fraisse, A., Sitbon, O., O'callaghan, D.S., Simonneau, G., Soubrier, F., and Humbert, M. (2010). Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. AmJRespir Crit Care Med 181, 851-861.
27. Gougos, A., and Letarte, M. (1990). Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265, 8361-8364.
28. Goumans, M.J., Valdimarsdottir, G., Itoh, S., Rosendahl, A., Sideras, P., and Ten Dijke, P. (2002). Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBOJ 21,1743-1753.
29. Gregory, A.L., Xu, G., Sotov, V., and Letarte, M. (2014). Review: the enigmatic role of endoglin in the placenta. Placenta 35 Suppl, S93-99. doi: 10.1016/j.placenta.2013.10.020.
30. Guzman, A., Zelman-Femiak, M., Boergermann, J.H., Paschkowsky, S., Kreuzaler, P.A., Fratzl, P., Harms, G.S., and Knaus, P. (2012). SMAD versus non-SMAD signaling is determined by lateral mobility of bone morphogenetic protein (BMP) receptors. J Biol Chem 287, 39492-39504.
31. Johnson, D.W., Berg, J.N., Baldwin, M.A., Gallione, C.J., Marondel, I., Yoon, S.J., Stenzel, T.T., Speer, M., Pericak-Vance, M.A., Diamond, A., Guttmacher, A.E., Jackson, C.E., Attisano, L., Kucherlapati, R., Porteous, M.E., and Marchuk, D.A. (1996). Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13,189-195.
32. Laux, D.W., Young, S., Donovan, J.P., Mansfield, C.J., Upton, P.D., and Roman, B.L. (2013). Circulating Bmp10 acts through endothelial Alk1 to mediate flow-dependent arterial quiescence. Development 140, 3403-3412.
33. Levet, S., Ciais, D., Merdzhanova, G., Mallet, C., Zimmers, T.A., Lee, S.J., Navarro, F.P., Texier, I., Feige, J.J., Bailly, S., and Vittet, D. (2013). Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formation. Blood 122, 598-607.
34. Li, D.Y., Sorensen, L.K., Brooke, B.S., Urness, L.D., Davis, E.C., Taylor, D.G., Boak, B.B., and Wendel, D.P. (1999). Defective angiogenesis in mice lacking endoglin. Science 284, 1534-1537.
35. Llorca, O., Trujillo, A., Blanco, F.J., and Bernabeu, C. (2007). Structural model of human endoglin, a transmembrane receptor responsible for hereditary hemorrhagic telangiectasia. J MolBiol 365, 694-705.
36. Lupu, A., Stefanescu, C., Treton, X., Attar, A., Corcos, O., and Bouhnik, Y. (2013). Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia. Journal of Clinical Gastroenterology 47, 256-257.
37. Lux, A., Gallione, C.J., and Marchuk, D.A. (2000). Expression analysis of endoglin missense and truncation mutations: insights into protein structure and disease mechanisms. Hum Mol Genet 9, 745-755.
38. Mahlawat, P., Ilangovan, U., Biswas, T., Sun, L.Z., and Hinck, A.P. (2012). Structure of the Alk1 extracellular domain and characterization of its bone morphogenetic protein (BMP) binding properties. Biochemistry 51, 6328-6341.
39. Mahmoud, M., Allinson, K.R., Zhai, Z., Oakenfull, R., Ghandi, P., Adams, R.H., Fruttiger, M., and Arthur, H.M. (2010). Pathogenesis of arteriovenous malformations in the absence of endoglin. CircRes 106,1425-1433.
40. Mallet, C., Lamribet, K., Giraud, S., Dupuis-Girod, S., Feige, J.J., Bailly, S., and Tillet, E. (2014). Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function. Hum Mol Genet. doi: 10.1093/hmg/ddu531.
41. Massague, J. (2008). TGFbeta in Cancer. Cell 134, 215-230.
42. McAllister, K.A., Grogg, K.M., Johnson, D.W., Gallione, C.J., Baldwin, M.A., Jackson, C.E., Helmbold, E.A., Markel, D.S., Mckinnon, W.C., Murrell, J., McCormick, M.K., Pericak-Vance, M.A., Heutink, P., Oostra, B.A., Haltjema, T., Westerman, C.J.J., Porteous, M.E., Guttmacher, A.E., Letarte, M., and Marchuk, D.A. (1994). Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8, 345-351.
43. Meurer, S.K., Alsamman, M., Scholten, D., and Weiskirchen, R. (2014). Endoglin in liver fibrogenesis: Bridging basic science and clinical practice. World J Biol Chem 5, 180-203. doi: 10.4331/wjbc.v5.i2.180.
44. Miller, A.F., Harvey, S.A., Thies, R.S., and Olson, M.S. (2000). Bone morphogenetic protein-9. An autocrine/paracrine cytokine in the liver. J Biol Chem 275,17937-17945.
45. Mitchell, A., Adams, L.A., Macquillan, G., Tibballs, J., Vanden Driesen, R., and Delriviere, L. (2008). Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 14, 210-213.
46. Neuhaus, H., Rosen, V., and Thies, R.S. (1999). Heart specific expression of mouse BMP-10 a novel member of the TGF-beta superfamily. Mech Dev 80,181-184.
47. Nolan-Stevaux, O., Zhong, W., Culp, S., Shaffer, K., Hoover, J., Wickramasinghe, D., and Ruefli-Brasse, A. (2012). Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies. PLoS One 7, e50920. doi: 10.1371/journal.pone.0050920.
48. Oh, S.P., Seki, T., Goss, K.A., Imamura, T., Yi, Y., Donahoe, P.K., Li, L., Miyazono, K., Ten Dijke, P., Kim, S., and Li, E. (2000). Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A 97, 2626-2631.
49. Paquet, M.E., Pece-Barbara, N., Vera, S., Cymerman, U., Karabegovic, A., Shovlin, C., and Letarte, M. (2001). Analysis of several endoglin mutants reveals no endogenous mature or secreted protein capable of interfering with normal endoglin function. Human Molecular Genetics 10, 1347-1357.
50. Park, J.E., Shao, D., Upton, P.D., Desouza, P., Adcock, I.M., Davies, R.J., Morrell, N.W., Griffiths, M.J., and Wort, S.J. (2012). BMP-9 induced endothelial cell tubule formation and inhibition of migration involves Smad1 driven endothelin-1 production. PLoS One 7, e30075. doi: 10.1371/journal.pone.0030075.
51. Park, S.O., Wankhede, M., Lee, Y.J., Choi, E.J., Fliess, N., Choe, S.W., Oh, S.H., Walter, G., Raizada, M.K., Sorg, B.S., and Oh, S.P. (2009). Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest 119, 3487-3496.
52. Pece, N., Vera, S., Cymerman, U., White, R.I., Jr., Wrana, J.L., and Letarte, M. (1997). Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative. J Clin Invest 100, 2568-2579.
53. Pece-Barbara, N., Cymerman, U., Vera, S., Marchuk, D.A., and Letarte, M. (1999). Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1. Human Molecular Genetics 8, 2171-2181.
54. Poorgholi Belverdi, M., Krause, C., Guzman, A., and Knaus, P. (2012). Comprehensive analysis of TGF-betaand BMP receptor interactomes. Eur J Cell Biol 91, 287-293.
55. Ricard, N., Bidart, M., Mallet, C., Lesca, G., Giraud, S., Prudent, R., Feige, J.J., and Bailly, S. (2010). Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations. Blood 116,1604-1612.
56. Ricard, N., Ciais, D., Levet, S., Subileau, M., Mallet, C., Zimmers, T.A., Lee, S.J., Bidart, M., Feige, J.J., and Bailly, S. (2012). BMP9 and BMP10 are critical for postnatal retinal vascular remodeling. Blood 119, 6162-6171.
57. Roman, B.L., Pham, V.N., Lawson, N.D., Kulik, M., Childs, S., Lekven, A.C., Garrity, D.M., Moon, R.T., Fishman, M.C., Lechleider, R.J., and Weinstein, B.M. (2002). Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels. Development 129, 3009-3019.
58. Scharpfenecker, M., Van Dinther, M., Liu, Z., Van Bezooijen, R.L., Zhao, Q., Pukac, L., Lowik, C.W., and Ten Dijke, P. (2007). BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 120, 964-972.
59. Sengle, G., Ono, R.N., Sasaki, T., and Sakai, L.Y. (2011). Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability. J Biol Chem 286, 5087-5099.
60. Spiekerkoetter, E., Tian, X., Cai, J., Hopper, R.K., Sudheendra, D., Li, C.G., El-Bizri, N., Sawada, H., Haghighat, R., Chan, R., Haghighat, L., De Jesus Perez, V., Wang, L., Reddy, S., Zhao, M., Bernstein, D., Solow-Cordero, D.E., Beachy, P.A., Wandless, T.J., Ten Dijke, P., and Rabinovitch, M. (2013). FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest 123, 3600-3613.
61. Srinivasan, S., Hanes, M.A., Dickens, T., Porteous, M.E., Oh, S.P., Hale, L.P., and Marchuk, D.A. (2003). A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 12, 473-482.
62. Susan-Resiga, D., Essalmani, R., Hamelin, J., Asselin, M.C., Benjannet, S., Chamberland, A., Day, R., Szumska, D., Constam, D., Bhattacharya, S., Prat, A., and Seidah, N.G. (2011). Furin is the major processing enzyme of the cardiac-specific growth factor bone morphogenetic protein 10. J Biol Chem 286, 22785-22794.
63. Suzuki, Y., Ohga, N., Morishita, Y., Hida, K., Miyazono, K., and Watabe, T. (2010). BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J Cell Sci 123,1684-1692.
64. Ten Dijke, P., and Arthur, H.M. (2007). Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 8, 857-869.
65. Torsney, E., Charlton, R., Diamond, A.G., Burn, J., Soames, J.V., and Arthur, H.M. (2003). Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality. Circulation 107,1653-1657.
66. Townson, S.A., Martinez-Hackert, E., Greppi, C., Lowden, P., Sako, D., Liu, J., Ucran, J.A., Liharska, K., Underwood, K.W., Seehra, J., Kumar, R., and Grinberg, A.V. (2012). Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex. J Biol Chem 287, 27313-27325.
67. Trembath, R.C., Thomson, J.R., Machado, R.D., Morgan, N.V., Atkinson, C., Winship, I., Simonneau, G., Galie, N., Loyd, J.E., Humbert, M., Nichols, W.C., Morrell, N.W., Berg, J., Manes, A., Mcgaughran, J., Pauciulo, M., and Wheeler, L. (2001). Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 345, 325-334.
68. Upton, P.D., and Morrell, N.W. (2009). TGF-beta and BMPR-II pharmacology--implications for pulmonary vascular diseases. Curr Opin Pharmacol 9, 274-280.
69. Urness, L.D., Sorensen, L.K., and Li, D.Y. (2000). Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 26, 328-331.
70. Van Meeteren, L.A., Thorikay, M., Bergqvist, S., Pardali, E., Stampino, C.G., Hu-Lowe, D., Goumans, M.J., and Ten Dijke, P. (2012). Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J Biol Chem 287, 18551-18561.
71. Vlachou, P.A., Colak, E., Koculym, A., Kirpalani, A., Kim, T.K., Hirschfield, G.M., and Faughnan, M.E. (2013). Improvement of ischemic cholangiopathy in three patients with hereditary hemorrhagic telangiectasia following treatment with bevacizumab. Journal of Hepatology 59,186-189.
72. Wooderchak-Donahue, W.L., Mcdonald, J., O'fallon, B., Upton, P.D., Li, W., Roman, B.L., Young, S., Plant, P., Fulop, G.T., Langa, C., Morrell, N.W., Botella, L.M., Bernabeu, C., Stevenson, D.A., Runo, J.R., and Bayrak-Toydemir, P. (2013). BMP9 mutations cause a vascularanomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia.Am J Hum Genet93, 530-537.
73. Xu, P., Liu, J., and Derynck, R. (2012). Post-translational regulation of TGF-beta receptor and Smad signaling. FEBS Lett 586,1871-1884.
74. Yoshimatsu, Y., Lee, Y.G., Akatsu, Y., Taguchi, L., Suzuki, H.I., Cunha, S.I., Maruyama, K., Suzuki, Y., Yamazaki, T., Katsura, A., Oh, S.P., Zimmers, T.A., Lee, S.J., Pietras, K., Koh, G.Y., Miyazono, K., and Watabe, T. (2013). Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression. Proc Natl Acad Sci USA 110,18940-18945.